POZEN clinical trials
Acquired by Aralez Pharmaceuticals, Feb 5, 2016 · source ↗
The registry lists 27 studies whose lead sponsor is POZEN. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 18, 2016.
Before and after it joined Aralez Pharmaceuticals
- First submitted before POZEN became part of Aralez Pharmaceuticals
- 27
- First submitted after POZEN became part of Aralez Pharmaceuticals
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- POZEN27 studies
Something wrong with this grouping? Tell us on the Aralez Pharmaceuticals page.
Studies
Recruiting first, then most recently updated. Showing 27 of 27. All Aralez Pharmaceuticals studies →
- A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated UlcersCompletedNCT00961350Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated UlcersCompletedNCT00960869Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric UlcersCompletedNCT00995410Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After BunionectomyCompletedNCT00293631Phase 2
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.CompletedNCT00293657Phase 2
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540CompletedNCT01557335Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With OsteoarthritisCompletedNCT00664560Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With OsteoarthritisCompletedNCT00665431Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) NaproxenCompletedNCT00527787Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) NaproxenCompletedNCT01129011Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to ArthrotecTerminatedNCT00594854Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)CompletedNCT00527904Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Phase I Study to Evaluate Bioavailability of Overencapsulated CelecoxibCompletedNCT00729495Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated AspirinCompletedNCT00441519Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With CelecoxibCompletedNCT00700687Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma LevelsCompletedNCT00749385Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Bioavailability of Naproxen 375 mg in Two FormulationsCompletedNCT00692055Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Effect of Food on the Bioavailability of PN400 ComponentsCompletedNCT00676442Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Bioavailability of Naproxen 500 mg in Three FormulationsCompletedNCT00665743Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- PK Study to Evaluate Esomeprazole Plasma Levels Following Administration of PN 400CompletedNCT00599404Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy VolunteersCompletedNCT00442208Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.CompletedNCT00367211Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluate Relative Bioavailability of PA32540 (Asa/Omeprazole), Its Aspirin Component, and Ecotrin® in Healthy VolunteersCompletedNCT00632086Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated AspirinCompletedNCT00442052Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 MonthsCompletedNCT00442221Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine HeadachesCompletedNCT00433732Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane HeadachesCompletedNCT00434083Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals